Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Gene therapy treatment for brain tumours and infections

Gene therapy treatment for brain tumours and infections

Lilly launches phase III trial of Enzastaurin

Lilly launches phase III trial of Enzastaurin

Target identified for therapeutic drugs to fight adult brain cancer

Target identified for therapeutic drugs to fight adult brain cancer

Study suggests a way to eliminate glioblastoma

Study suggests a way to eliminate glioblastoma

Researchers can now identify patients likely to respond to cancer drug therapy

Researchers can now identify patients likely to respond to cancer drug therapy

Combination of radiotherapy and a drug named S247 as a cure for cancer

Combination of radiotherapy and a drug named S247 as a cure for cancer

EphA2 represents a promising treatment target for glioblastoma multiforme

EphA2 represents a promising treatment target for glioblastoma multiforme

Researchers at Johns Hopkins have identified three new genetic mutations in brain tumors

Researchers at Johns Hopkins have identified three new genetic mutations in brain tumors

Mutations in receptor tyrosine kinases provide potential for highly-targeted cancer therapies

Mutations in receptor tyrosine kinases provide potential for highly-targeted cancer therapies

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Asthma may be linked to a decreased risk of brain cancer

Asthma may be linked to a decreased risk of brain cancer

Having asthma, hay fever or another allergic condition may reduce the risk of developing Glioblastoma multiforme

Having asthma, hay fever or another allergic condition may reduce the risk of developing Glioblastoma multiforme

Study examines biomarkers for response to erlotinib in glioma

Study examines biomarkers for response to erlotinib in glioma

Chemotherapy for brain tumors is boosted after vaccine targets resistance-related TRP-2 antigen

Chemotherapy for brain tumors is boosted after vaccine targets resistance-related TRP-2 antigen

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Virus that targets and kills glioblastoma

Virus that targets and kills glioblastoma

Research offers new molecular approaches to therapies for the most deadly cancers

Research offers new molecular approaches to therapies for the most deadly cancers

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

Isotopes for society

Isotopes for society

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.